These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 24841451

  • 1. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
    Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.
    J Med Econ; 2015 Jan; 18(1):37-44. PubMed ID: 24841451
    [Abstract] [Full Text] [Related]

  • 2. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B, Rahman M, Waters HC, Callegari P.
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP, Buckley F, Dejonckheere F, Ogale S.
    Health Qual Life Outcomes; 2014 Jul 03; 12():102. PubMed ID: 24988902
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 Jul 03; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 5. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct 03; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 6. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 03; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 7. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
    Gabay C, Hasler P, Kyburz D, So A, Villiger P, von Kempis J, Walker U.
    Swiss Med Wkly; 2014 Nov 03; 144():w13950. PubMed ID: 24723273
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun 03; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 9. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.
    PLoS One; 2012 Jun 03; 7(1):e30275. PubMed ID: 22272322
    [Abstract] [Full Text] [Related]

  • 10. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
    Liu Y, Fan W, Chen H, Yu MX.
    Asian Pac J Cancer Prev; 2014 Jun 03; 15(8):3403-10. PubMed ID: 24870729
    [Abstract] [Full Text] [Related]

  • 11. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct 03; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep 03; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 13. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G, Hollan I, Førre O, Wiik A, Lyberg T, Mikkelsen K, Agewall S.
    Clin Exp Rheumatol; 2013 Sep 03; 31(3):415-21. PubMed ID: 23465067
    [Abstract] [Full Text] [Related]

  • 14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 03; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 15. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul 03; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 16. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.
    Curr Med Res Opin; 2007 Aug 03; 23(8):1749-59. PubMed ID: 17588306
    [Abstract] [Full Text] [Related]

  • 17. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.
    Adv Ther; 2012 Mar 03; 29(3):234-48. PubMed ID: 22411424
    [Abstract] [Full Text] [Related]

  • 18. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May 03; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 19. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
    Harley CR, Frytak JR, Tandon N.
    Am J Manag Care; 2003 Oct 03; 9(6 Suppl):S136-43. PubMed ID: 14577718
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 03; 24(5):715-24. PubMed ID: 24313916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.